The guidelines recommend CHB patients with abnormal ALT or pathological evidence of moderate-to-severe active necroinflammation or a minimum of moderate fibrosis for NAs treatment.22,26 However, in some CHB patients, ALT levels may remain within the normal range whereas the liver experiences active necroinflammation or liver fibrosis. This evidence concerns the gene GPT and Hepatic fibrosis.